Research ArticleClinical Studies
Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
TAKEHIRO TOZUKA, NORIKO YANAGITANI, HIROSHI YOSHIDA, RYO MANABE, SHINSUKE OGUSU, RYOSUKE TSUGITOMI, HIROAKI SAKAMOTO, YOSHIAKI AMINO, RYO ARIYASU, KEN UCHIBORI, SATORU KITAZONO, MASAHIRO SEIKE, AKIHIKO GEMMA and MAKOTO NISHIO
Anticancer Research April 2021, 41 (4) 2093-2100; DOI: https://doi.org/10.21873/anticanres.14980
TAKEHIRO TOZUKA
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
NORIKO YANAGITANI
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
HIROSHI YOSHIDA
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
RYO MANABE
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
SHINSUKE OGUSU
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
RYOSUKE TSUGITOMI
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
HIROAKI SAKAMOTO
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
YOSHIAKI AMINO
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
RYO ARIYASU
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
KEN UCHIBORI
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
SATORU KITAZONO
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;
MASAHIRO SEIKE
2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
AKIHIKO GEMMA
2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
MAKOTO NISHIO
1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;

Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
patientACCESS
patientACCESS - Patients desiring access to articles
In this issue
Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
TAKEHIRO TOZUKA, NORIKO YANAGITANI, HIROSHI YOSHIDA, RYO MANABE, SHINSUKE OGUSU, RYOSUKE TSUGITOMI, HIROAKI SAKAMOTO, YOSHIAKI AMINO, RYO ARIYASU, KEN UCHIBORI, SATORU KITAZONO, MASAHIRO SEIKE, AKIHIKO GEMMA, MAKOTO NISHIO
Anticancer Research Apr 2021, 41 (4) 2093-2100; DOI: 10.21873/anticanres.14980
Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
TAKEHIRO TOZUKA, NORIKO YANAGITANI, HIROSHI YOSHIDA, RYO MANABE, SHINSUKE OGUSU, RYOSUKE TSUGITOMI, HIROAKI SAKAMOTO, YOSHIAKI AMINO, RYO ARIYASU, KEN UCHIBORI, SATORU KITAZONO, MASAHIRO SEIKE, AKIHIKO GEMMA, MAKOTO NISHIO
Anticancer Research Apr 2021, 41 (4) 2093-2100; DOI: 10.21873/anticanres.14980
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.